

<b>Wednesday 14th June</b>				
8:00 – 9:45	<b>Registration</b>			
9:45 – 10:45	<b>Building a Better Bridge: Innovations in Trial Designs to Address Access and Clinical Practice Questions (Launch &amp; Lifestyle SIG)</b>	<b>High Dimensional Data</b>	<b>Learning From Mistakes</b>	<b>Data Sharing SIG</b>
	Jenny Devenport (Roche)	Chris Harbron (Roche) <i>Machine Learning and Artificial Intelligence in Clinical Statistics. An opportunity or an over-hyped distraction?</i>	Sue McKendrick (PPD)  Mary Oldham (GSK)  Emma Jones (Veramed)	Speakers TBC
	Cornelia Dunger-Baldauf (Novartis)	Kaya Miah (German Cancer Research Centre, DKFZ) <i>Model selection strategies for multi-state endpoints incorporating molecular data</i>		
	Alexander Schacht (Sanevidence)	Robin Mitra (University College London) <i>Addressing Structured Missingness in large complex health databases</i>		
<b>Changeover</b>				
10:45 – 11:00				
11:00 – 12:30	<b>The Art of Selecting a Subgroup (Subgroup SIG)</b>	<b>What is real - RWD or RCT? How to communicate evidence generation involving RWD (RWD + Launch &amp; Lifestyle SIG)</b>	<b>Adaptive Designs: What, Why, When and How Should I use Them?</b>	<b>Estimands – The Journey Continues or Doing now what Trial Teams Need Next (Oncology Estimand SIG)</b>
	Paolo Eusebi (Modus Outcomes) <i>Data-Driven Subgroup Identification in Clinical Trials: the Good, the Bad, the Ugly</i>	Josephine Wolfram (Astellas) <i>Introduction</i>	Dr Thomas Burnett (University of Bath)  Dr Sofia Vilar (University of Cambridge)	Lynda Grinsted (AstraZeneca)  Stefan Englert (Janssen)  Elizabeth Pilling (AstraZeneca)

	Nicole Kraemer (Boehringer Ingelheim) <i>Using simulation studies to evaluate subgroup identification methods</i>	Min-Hua Jen (Eli Lilly) <i>Case Study</i>	Professor Christopher Jennison (University of Bath)	Hong Tian (BeiGene)  Yufei Wang (GSK)  Konstantina Skaltsa (IQVIA)
	Yuejia Xu (AstraZeneca) <i>Honest Estimation of Treatment Effects in Subgroups</i>	Alexander Schacht (Sanevidence) <i>Good Communication Practice</i>		
12:30 – 13:30	<b>Lunch (HTA ESIG Social catch-up)</b>			
13:30 – 14:30	<b>PSI/RSS Prize Winner</b>	<b>Master Protocols</b>	<b>Vaccine SIG</b>	<b>Non-technical TED talks</b>
	Marcel Wolbers (Roche) & Alessandro Noci (Roche) <i>Standard and reference-based imputation methods based on conditional mean imputation</i>	Jason Cooper (AstraZeneca) <i>Feasibility of a Platform Phase II trial for Moderate-to-Severe Asthma: Obstacles and Opportunities</i>	Hege Michiels (Ghent University) <i>Estimation and Interpretation of Vaccine Efficacy in COVID-19 Randomized Clinical Trials</i>	Kimberley Hacquoil (Exploristics) <i>Deal or No Deal: Make a Decision</i>
		Michaela Maria Freitag (Charité University) <i>Design Considerations for a Phase II Platform Trial in Major Depressive Disorder</i>	Andrea Callegaro (GSK) <i>Bayesian Dynamic Borrowing (BDB) and Vaccine Effectiveness: The Boostrix Maternal Immunization US case</i>	Emma May (ICON) <i>Building community in a virtual environment</i>
				Ian Ratcliffe (Veramed) <i>I Want to Fail!</i>
Bob Murray (Janssen) <i>Communication of Statistics: The Formula for Success</i>				

		Peter Jacko (Berry Consultants) <i>Designing and Simulating a Platform Trial for Rare Diseases</i>	Daniel Backenroth (Janssen) <i>Negative Control Methods for Assessing the Robustness of Open-Label Analysis of COVID-19 Vaccine Trial</i>	Amy Newlands (GSK) <i>Increasing Statistics Capability in sub-Sahara Africa - The Next Wave</i>
				Eileen Holmes (PHASTAR) <i>Supporting People in FSP Roles</i>
14:30 – 15:00	<b>Break</b>			
15:00 – 16:15	<p><b>EU HTA: readying ourselves for the road to 2025 and beyond</b></p> <p>Anders Gorst-Rasmussen (Novo Nordisk) <i>In the crystal ball: how the world might look for a pharmaceutical statistician when EU HTA is here</i></p> <p>Ralf Bender (IQWiG) <i>German requirements for direct and indirect comparisons in HTA dossiers</i></p> <p>Zoe Garrett (NICE) Where can collaboration add value to HTA – A look at the UK, Australia and Canada</p> <p>Justine Rochon (Boehringer Ingelheim) <i>Statistical leadership: Do we hold the key to the future of HTA?</i></p>			
16:15 – 16:30	<b>Closing Remarks</b>			